DaVita Inc. $DVA Shares Bought by ING Groep NV

ING Groep NV raised its holdings in DaVita Inc. (NYSE:DVA) by 418.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,321 shares of the company’s stock after purchasing an additional 10,753 shares during the period. ING Groep NV’s holdings in DaVita were worth $1,513,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Elevation Wealth Partners LLC grew its holdings in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the period. Canada Pension Plan Investment Board acquired a new stake in DaVita in the second quarter valued at approximately $43,000. iSAM Funds UK Ltd acquired a new stake in DaVita in the third quarter valued at approximately $46,000. Stance Capital LLC acquired a new stake in DaVita in the third quarter valued at approximately $47,000. Finally, Fideuram Asset Management Ireland dac acquired a new stake in DaVita in the fourth quarter valued at approximately $49,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of DaVita stock opened at $198.19 on Wednesday. DaVita Inc. has a one year low of $101.00 and a one year high of $202.69. The company has a market cap of $12.72 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 0.63 and a beta of 0.91. The business’s 50 day moving average price is $173.05 and its 200 day moving average price is $144.47.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the business posted $2.00 earnings per share. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on DVA shares. TD Cowen raised their price objective on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. UBS Group raised their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Barclays raised their target price on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DaVita has an average rating of “Hold” and an average price target of $199.17.

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.